Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

Bernard Escudier1, Jan Cosaert2, Sangeeta Jethwa21Unit&eacute; Immunoth&eacute;rapie, Institut Gustave Roussy, Villejuif, France; 2F. Hoffmann-La Roche Ltd, Basel, SwitzerlandAbstract: Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effectiv...

Full description

Bibliographic Details
Main Authors:	Bernard Escudier, Jan Cosaert, Sangeeta Jethwa
Format:	Article
Language:	English
Published:	Dove Medical Press 2008-09-01
Series:	Biologics : Targets & Therapy
Online Access:	http://www.dovepress.com/targeted-therapies-in-the-management-of-renal-cell-carcinoma-role-of-b-a2301

Similar Items

Targeted therapies in the management of colorectal carcinoma: role of bevacizumab
by: Ajithkumar Puthillath, et al.
Published: (2008-11-01)

Indirect treatment comparison of bevacizumab + interferon-&alpha;-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
by: Gerald HJ Mickisch, et al.
Published: (2011-01-01)

Temsirolimus in the treatment of advanced renal cell carcinoma
by: Bernard J. Escudier
Published: (2011-12-01)

Temsirolimus in the treatment of advanced renal cell carcinoma
by: Bernard J. Escudier
Published: (2011-12-01)

The bevacizumab experience in advanced renal cell carcinoma
by: Lauren C Harshman, et al.
Published: (2010-09-01)

Metastatic renal cell carcinoma management
by: Flavio L. Heldwein, et al.
Published: (2009-06-01)

The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
by: Jaya Unnithan, et al.
Published: (2007-01-01)

Current Management of Renal Cell Carcinoma and Targeted Therapy
by: A Erdem Canda, et al.
Published: (2006-03-01)

Role of bevacizumab therapy in the management of glioblastoma
by: Scott J Peak, et al.
Published: (2010-04-01)

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
by: Sylvie Négrier, et al.
Published: (2017-08-01)

Nivolumab in renal cell carcinoma: latest evidence and clinical potential
by: Camille Mazza, et al.
Published: (2017-03-01)

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
by: Sepe P, et al.
Published: (2020-11-01)

Targeted Therapy for Metastatic Renal Cell Carcinoma
by: Andika Afriansyah, et al.
Published: (2017-02-01)

Targeted therapy of advanced renal cell carcinoma
by: A. M. Popov
Published: (2017-06-01)

Targeted therapy for metastatic renal cell carcinoma
by: Camillo Porta, et al.
Published: (2014-09-01)

Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma
by: Lisa Derosa, et al.
Published: (2016-11-01)

Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
by: Peter E Clark
Published: (2010-06-01)

Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
by: Ronald M Bukowski
Published: (2010-03-01)

Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy
by: Trace M. Jones, et al.
Published: (2020-05-01)

Progress in targeted therapy for metastatic renal cell carcinoma
by: Yu-Sheng Wang1 ,, et al.
Published: (2019-10-01)

Targeted therapy for renal cell carcinoma: The next lap
by: Ravindran Kanesvaran, et al.
Published: (2014-01-01)

Neoadjuvant targeted therapy in patients with renal cell carcinoma
by: B. Ya. Alekseev, et al.
Published: (2015-06-01)

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer
by: Ananaya Datta-Mitra, et al.
Published: (2014-01-01)

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
by: Jeffrey J. Wallin, et al.
Published: (2016-08-01)

Ciliary body metastasis from renal cell carcinoma successfully treated with intravitreal bevacizumab
by: Margaret Wong, MD, et al.
Published: (2017-06-01)

The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma
by: Leonardo D. Borregales, et al.
Published: (2016-04-01)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
by: Andrew J. Wiele, et al.
Published: (2021-04-01)

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer: Erratum
Published: (2015-01-01)

IDENTIFICATION OF PROGNOSTIC FACTORS OF THE EFFICIENCY OF BEVACIZUMAB THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CANCER
by: B. Ya. Alekseyev, et al.
Published: (2014-07-01)

IDENTIFICATION OF PROGNOSTIC FACTORS OF THE EFFICIENCY OF BEVACIZUMAB THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CANCER
by: B. Ya. Alekseyev, et al.
Published: (2014-07-01)

Autophagy as a Vital Therapy Target for Renal Cell Carcinoma
by: Ying-hua He, et al.
Published: (2021-02-01)

Targeted Therapy for Renal Cell Carcinoma: a Prospective study
by: Robin Joshi, et al.
Published: (2015-06-01)

Targeted Therapy for Renal Cell Carcinoma: a Prospective study
by: Robin Joshi, et al.
Published: (2015-06-01)

Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma
by: Alessandro Conti, et al.
Published: (2013-01-01)

Targeted therapy in patients with poor-prognosis renal cell carcinoma
by: B. Ya. Alekseev, et al.
Published: (2017-06-01)

NEW CAPACITIES OF TARGETED THERAPY FOR METASTATIC RENAL-CELL CARCINOMA
by: B. Ya. Alekseyev, et al.
Published: (2014-08-01)

NEW CAPACITIES OF TARGETED THERAPY FOR METASTATIC RENAL-CELL CARCINOMA
by: B. Ya. Alekseyev, et al.
Published: (2014-08-01)

The role of sunitinib in the therapy of metastatic renal cell carcinoma
by: I. G. Rusakov, et al.
Published: (2020-07-01)

Targeted Therapy for Metastatic Renal Carcinoma: An Update
by: Rodrigo Donalisio da Silva, et al.
Published: (2014-10-01)

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation
by: J Thompson Coon, et al.
Published: (2010-01-01)